After a somewhat sluggish start, Aurobindo’s biosimilars business is building up momentum, with the firm’s CuraTeQ Biologics unit picking up its latest approval – this time, for a UK bevacizumab rival to Avastin.
CuraTeQ’s Bevqolva biosimilar has been granted a marketing authorization by the UK’s Medicines and Healthcare products Regulatory Agency as a 25mg/ml concentrate for infusion that will be
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Generics Bulletin for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?